Indivior PLC (the 'Company')
Indivior PLC confirms that Mr Daniel Tassé, Senior Independent Director, was appointed as an independent director of HLS Therapeutics Inc., a specialty pharmaceutical company listed on the TSX Venture Exchange, with effect from March 14, 2018.
This announcement is made in accordance with Listing Rule 9.6.14.
Kathryn Hudson
Company Secretary